Download Curriculum Vitae

Dr. Courtney is originally from New Hampshire. He initially was drawn to cancer research as an undergraduate at Dartmouth College, where he studied chromium carcinogenesis in the laboratory of Dr. Karen Wetterhahn. He received his M.D. and his Ph.D. in molecular cancer biology from Duke University through the Medical Scientist Training Program. After completing his residency training in Internal Medicine at the University of California, San Francisco, Dr. Courtney completed his medical oncology fellowship at the Dana-Farber Cancer Institute / Dana-Farber Harvard Cancer Center. There he pursued post-doctoral studies in signal transduction and cancer metabolism in the laboratory of Dr. Lewis Cantley. Following his fellowship, Dr. Courtney continued on as faculty at Harvard Medical School and as an attending oncologist at Dana-Farber in the Lank Center for Genitourinary Oncology.

Dr. Courtney joined the faculty at UT Southwestern in 2012. He specializes in genitourinary malignancies, with an emphasis on prostate and kidney cancer. Dr. Courtney's research efforts are focused on developing investigator-initiated clinical trials in prostate and kidney cancer that draw on his background in laboratory research and through collaborations with the outstanding basic scientists at UTSW.


Other Post Graduate Training
Duke University School of Medicine (2001)
Graduate School
Duke University School of Medicine (2001)
Medical School
Duke University School of Medicine (2002)
University of California, San Francisco (2005), Internal Medicine
Dana-Farber Cancer Institute (2008), Oncology

Research Interest

  • Clinical-translational research in genitourinary oncology
  • Industry- and cooperative group-sponsored trials in genitourinary malignancies
  • Investigator-initiated clinical trials in kidney cancer
  • Investigator-initiated clinical trials in prostate cancer
  • Novel biomarkers and therapeutics in prostate and kidney cancer


Featured Publications LegendFeatured Publications

HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma.
Courtney KD*, Ma Y*, Diaz de Leon A*, Christie A, Xie Z, Woolford L, Singla N, Joyce A, Hill H, Madhuranthakam AJ, Yuan Q, Xi Y, Zhang Y, Chang J, Fatunde O, Arriaga Y, Frankel AE, Kalva S, Zhang S, McKenzie T, Reig Torras O, Figlin RA, Rini BI, McKay RM, Kapur P, Wang T, Pedrosa I, Brugarolas J. Clin Cancer Res. 2019
Salvage Radiotherapy for Nodal Oligorecurrent Prostate Cancer: A Step Towards Predictive Criteria for Metastasis-Directed Therapy in Prostate Cancer?
Desai NB, Courtney K, Subramaniam RM, Cadeddu JA. Eur Urol. 2019 76 740-742
MCT2 mediates concentration-dependent inhibition of glutamine metabolism by MOG.
Fets L, Driscoll PC, Grimm F, Jain A, Nunes PM, Gounis M, Doglioni G, Papageorgiou G, Ragan TJ, Campos S, Silva Dos Santos M, MacRae JI, O'Reilly N, Wright AJ, Benes CH, Courtney KD, House D, Anastasiou D Nat. Chem. Biol. 2018 Nov 14 11 1032-1042


Featured Books Legend Featured Books

Honors & Awards

  • John W. Boddie, Ph.D. & Joan Reisch, Ph.D. Fund in Prostate Cancer Research in Honor of Dr. Kevin Courtney
  • Wheels for Wellness Classic Hero Award of Gratitude from the Wheels for Wellness Foundation and Moncrief Cancer Institute
  • UT Southwestern Golden Pager Award
  • Career Development Award
    Genentech, Inc. Dana-Farber/Partners Cancer Center (2008)
  • Young Investigator Award
    American Society of Clinical Oncology (2008)
  • Sigma Xi
    Member (1993)
  • Phi Beta Kappa
    Membership (1992)

Professional Associations/Affiliations

  • American Society of Clinical Oncology (2008)